J.B. Chemicals & Pharmaceuticals Lt
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, the company offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. It provides its products to gastroenterology, anti-infectives, wound care, neonatology and pediatrics, gynaecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Strong 5-year net profit CAGR of 15.2%
Concerns0
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ3.72 K Cr | β | βΉ653.00 Cr | β | β | 19.3% | 12.9% | 20.3% |
| Mar 2024 | βΉ3.30 K Cr | β | βΉ543.00 Cr | β | β | 18.8% | 14.4% | 39.6% |
| Mar 2023 | βΉ2.88 K Cr | β | βΉ389.00 Cr | β | β | 15.9% | 31.7% | 7.8% |
| Mar 2022 | βΉ2.19 K Cr | β | βΉ361.00 Cr | β | β | 17.2% | 15.8% | -19.2% |
| Mar 2021 | βΉ1.89 K Cr | β | βΉ447.00 Cr | β | β | 24.8% | 15.3% | 66.8% |
| Mar 2020 | βΉ1.64 K Cr | β | βΉ268.00 Cr | β | β | 18.5% | 9.3% | 47.3% |
| Mar 2019 | βΉ1.50 K Cr | β | βΉ182.00 Cr | β | β | 12.3% | 20.1% | 42.2% |
| Mar 2018 | βΉ1.25 K Cr | β | βΉ128.00 Cr | β | β | 8.8% | 6.4% | -26.0% |
| Mar 2017 | βΉ1.18 K Cr | β | βΉ173.00 Cr | β | β | 12.5% | 2.7% | -3.4% |
| Mar 2016 | βΉ1.14 K Cr | β | βΉ179.00 Cr | β | β | 14.6% | 7.8% | 57.0% |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 3,877 |
| Total Expenses | 2,810 |
| EBIT / Operating Profit | 1,068 |
| OPM % | 28% |
| Other Income | 49 |
| Finance Costs | 4 |
| Depreciation & Amortisation | 170 |
| Profit Before Tax | 942 |
| Tax % | - |
| Net Profit / PAT | 704 |
| EPS (βΉ) | 45.15 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| J.B. Chemicals & Pharmaceuticals Ltthis co. | βΉ29.22 K Cr | βΉ3.72 K Cr | 41.50 | 7.85 | 32.06 | 12.9% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |